Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Preclinical program of translational research tasked with identifying new target proteins.

Sanofi and the Curie Institute, through its Curie-Cancer partnership under the Institut Carnot label, today announce the establishment of a three-year research collaboration to identify new therapeutic targets for the development of treatments for ovarian cancer.

The aim of the collaboration between Sanofi and Curie-Cancer is to revisit the basic biology of this type of cancer through a translational research approach. The Institut Curie has a large collection of cryopreserved tumor samples that are well characterized clinically, histologically and biologically. These can be analyzed to identify biological targets relevant to the effective treatment of certain types of cancer. Through this collaboration, Sanofi and Curie-Cancer expect to gain a better understanding of the molecular alterations that characterize many types of ovarian cancer, thereby enabling effective new drugs to be designed.

"We hope this type of long-term collaboration will ultimately open up perspectives for new therapeutic options for women with this disease. It will combine the accumulated knowledge on ovarian cancer gathered over many years by oncologists and biologists at the Institut Curie with the expertise of researchers from Sanofi's research and product development teams," said Dr. Debasish Roychowdhury, senior vice president and head of Sanofi Oncology. "Established under the Aviesan[1] partnership, this research agreement is a good example of translational research involving French scientific excellence."

"It is currently hard to tackle ovarian cancer. There are very few drugs available. We are very happy to collaborate with Sanofi to potentially provide our patients with additional therapeutic solutions. Sanofi's expertise in the selection of therapeutic targets is complementary to the know-how and technology platforms developed at the Institut Curie," said Damien Salauze, director of Curie-Cancer.

Using technology platforms developed at the Institut Curie by scientific teams led by Dr. Xavier Sastre-Garau and Dr. Sergio Roman-Roman, this program will make it possible to sequence molecules expressed by the tumor genome, compare the sequences of those obtained with non-tumor tissues from the same patients and then clarify and validate the nature of the molecular alterations that are identified. Sanofi's expertise in the selection of therapeutic targets will then guide an assessment of the tumor's ability to be inhibited or stimulated by drugs.

Ovarian cancer is still difficult to treat, despite recent advances. The main risk factor is advancing age, as well as a known hereditary factor in 5-10 per cent of cases. They are most often diagnosed late. The current therapeutic strategy of combining surgery and chemotherapy is effective, but relapses are frequent and the condition gradually becomes resistant to medical treatment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Bio-Mimicry Method For Preparing & Labeling Stem Cells Developed
Method allows researchers to prepare mesenchymal stem cells and monitor them using MRI.
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
New Bio-Glass Could Make it Possible to Re-Grow or Replace Cartilage
Researchers at Imperial College London have developed a material that can mimic cartilage and potentially encourage it to re-grow.
Stem Cell Advance Could Be Key Step Toward Treating Deadly Blood Diseases
UCLA scientists get closer to creating blood stem cells in the lab.
Harnessing Engineered Slippery Surfaces For Tissue Repair
A new method could facilitate the transfer of intact regenerating cell sheets from the culture dish to damaged tissues in patients.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!